Article · 20 May 2025
OtherPublished 22 Jul 2016
Lapatinib in the management of breast cancer
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Lapatinib is licensed for use in combination with capecitabine for the treatment of patients with progressive advanced breast cancer whose tumors overexpress the human epidermal growth factor receptor 2 (HER2/erbB2/HER2-neu), following therapy with an anthracycline, a taxane and trastuzumab. Lapatinib targets both the epidermal growth factor receptor (EGFR/HER1/erbB1) and HER2, and represents one of the most promising of a number of pharmacological attempts to bypass resistance mechanisms to trastuzumab. Further studies are being conducted to examine the potential role of lapatinib in the management of breast cancer in both the early and advanced setting. This article evaluates the pharmacology, tolerability and clinical efficacy of lapatinib. The future roles of lapatinib in the treatment of breast cancer are also discussed.
Keywords
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Clinical Practice.
Article · 20 May 2025
Histological effects of doxorubicin and baobab plants on some organs of rat
Article · 28 Mar 2025
Using
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Practice
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Peter S Hall”
- BylineArticles whose byline prints “Jaishree Bhosle”
- BylineArticles whose byline prints “David A Cameron”